BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23133312)

  • 21. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD73: a potent suppressor of antitumor immune responses.
    Beavis PA; Stagg J; Darcy PK; Smyth MJ
    Trends Immunol; 2012 May; 33(5):231-7. PubMed ID: 22487321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the CD39-CD73-adenosine pathway in liver disease.
    Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
    J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39.
    Goueli SA; Hsiao K
    PLoS One; 2019; 14(10):e0220094. PubMed ID: 31652269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.
    Flores-Santibáñez F; Fernández D; Meza D; Tejón G; Vargas L; Varela-Nallar L; Arredondo S; Guixé V; Rosemblatt M; Bono MR; Sauma D
    Immunology; 2015 Dec; 146(4):582-94. PubMed ID: 26331349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
    Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
    J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production.
    Kaku H; Cheng KF; Al-Abed Y; Rothstein TL
    J Immunol; 2014 Dec; 193(12):5904-13. PubMed ID: 25392527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73.
    Shi C; Chang L; Wang J; Dai J; Xu W; Tang J; Mei W; Zhang C; Wang Z; Liao Y; Zhang X; Jiang W; Zhang G; Zhao Z; Xu Y; Zhu L; Li H
    J Med Chem; 2024 Jun; 67(11):9686-9708. PubMed ID: 38809692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Immune Regulatory Role of Adenosine in the Tumor Microenvironment.
    Xing J; Zhang J; Wang J
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
    Bönner F; Borg N; Burghoff S; Schrader J
    PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme activity of circulating CD73 in human serum.
    Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
    Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular adenosine produced by ecto-5'-nucleotidase (CD73) regulates macrophage pro-inflammatory responses, nitric oxide production, and favors Salmonella persistence.
    Costales MG; Alam MS; Cavanaugh C; Williams KM
    Nitric Oxide; 2018 Jan; 72():7-15. PubMed ID: 29108754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Tumor-derived Exosomes Expressing CD73: New Opportunities in the Pathogenesis and Treatment of Cancer.
    Nooshabadi VT; Arab S
    Curr Mol Med; 2021; 21(6):476-483. PubMed ID: 33222670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
    Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
    Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
    Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
    BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5'NT/CD73 in metastasis as potential prognostic factor.
    Cappellari AR; Rockenbach L; Dietrich F; Clarimundo V; Glaser T; Braganhol E; Abujamra AL; Roesler R; Ulrich H; Battastini AM
    PLoS One; 2012; 7(10):e47468. PubMed ID: 23094051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD73: a novel target for cancer immunotherapy.
    Zhang B
    Cancer Res; 2010 Aug; 70(16):6407-11. PubMed ID: 20682793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.